Depemokimab is being developed as a treatment for individuals with moderate to severe Chronic Obstructive Pulmonary Disorder (COPD). The aim of this study is to assess the efficacy and safety of early initiation of depemokimab as an add-on medicine in participants with moderate to severe COPD with type 2 inflammation.

Inclusion Criteria:

• Male or eligible female participants

• Eosinophilic phenotype measured using Blood Eosinophil Count (BEC)

• Moderate to severe COPD, defined as

  • A clinically documented history of COPD for at least 1 year
  • A post-salbutamol Forced expiratory volume in one second (FEV1)/Forced vital capacity (FVC) ratio of less than (<)0.70 and a post-salbutamol FEV1 greater than (>)30 percent (%) and <80% predicted normal values

• Elevated risk for exacerbations, defined as

  • A well-documented history of only 1 moderate COPD exacerbation in the prior 12 months and
  • The presence of risk factors for future exacerbations/deterioration such as:
  • Modified Medical Research Council (mMRC) dyspnea score >= 2
  • COPD Assessment Test (CAT) >= 15
  • Post-bronchodilator FEV1 < 50% predicted
  • Chronic bronchitis

• Smoking status: Current or former cigarette smokers with a history of cigarette smoking of >=10 pack-years at Screening.

• Dual (Inhaled corticosteroid (ICS)+ Long-acting beta2-adrenergic receptor agonist [LABA] or LABA+ Long-acting muscarinic receptor antagonist [LAMA]) or triple (ICS+LABA+LAMA) inhaler therapy as assessed by the investigator for at least 3 months

• Body mass index (BMI) >=16 kilograms per square meter (kg/m^2)

Exclusion Criteria:

• The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of lung disease, and clinical manifestations of lung disease where primary diagnosis is not COPD are excluded

  • Participants with a current or prior physician diagnosis of asthma
  • Participants with childhood asthma are permitted, provided that childhood asthma has resolved before 18 years of age and has not recurred

• Other clinically significant lung disease: The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of the lung disease.

• COPD severity: Participants with more than one moderate exacerbation or severe exacerbation in the past 12 months prior to Visit 1

• COPD stability: Participants with pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Visit 1

• Lung resection: Participants with a history of, or plan for lung volume reduction surgery/endobronchial valve procedure

• Pulmonary rehabilitation: Participants in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1

• Chronic hypercapnia requiring non-invasive positive pressure ventilation (NIPPV) use including Bi-Level Positive Airway Pressure (BiPAP) or Continuous Positive Airway Pressure (CPAP) are excluded

• Continuous oxygen: Participants requiring oxygen supplementation for COPD

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About\_GSK\_Patient\_Level\_Data\_Sharing\_Final\_13July2023.pdf

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

This will be a double-blind study in which participants care providers investigators and outcome assessors will be blinded to the study intervention.